Zai Lab Ltd
NASDAQ · ZLAB·Shanghai, China·Mid-cap·Approved
Commercial-stage biopharma focused on discovering and commercializing innovative therapies across oncology, immunology, and neuroscience, primarily in Greater China. Has eight marketed products including ZEJULA, VYVGART, and COBENFY. Lead global pipeline asset Zoci is a DLL3-targeting ADC for small cell lung cancer.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Zai Lab Corporate Presentation | Corporate overview | February 26, 2026 | 22 |